Mieloma Multiple - Mieloma.com

Hablando de la IMF: estoy suscrita por E.Mail a "Myeloma Minute".
Me han mandado estas noticias, hoy.
cita:

 "Welcome to the IMF's Myeloma Minute
News about myeloma treatment, research, support and the myeloma community
from the International Myeloma Foundation.

    * What's News
    * What's New in Research
    * Upcoming Seminars and Clinical Conferences
    * Upcoming Events

    

    * Items of Interest
    * Help the IMF
    * Donate to the IMF

 
WHAT'S NEWS


The IMF would like to welcome Loraine Boyle as the newest member of the foundation's Board of Directors.
Loraine became involved with the IMF after losing her husband, the actor Peter Boyle, to myeloma. She is a writer and editor, and is active in community organizations and fundraising for her alma mater, Brown University.


NEW! The Myeloma Managerâ„¢ Personal Care Assistantâ„¢
Another exciting first from the IMF!
Free software to help manage and understand your lab results, and more!

EMEA Recommends New Contraindication For Velcade (bortezomib), EuropeThe European Medicines Agency (EMEA) has recommended that VELCADE (bortezomib) should not be used in multiple myeloma patients who are diagnosed with either acute diffuse infiltrative pulmonary disease or pericardial disease.
Â
The EMEA’s Committee for Medicinal Products for Human Use (CHMP) concluded during its March 2008 meeting that the benefits of VELCADE are greater than its risks, except in patients with acute diffuse infiltrative pulmonary and pericardial disease. The CHMP therefore recommended contraindicating the use of VELCADE for these patients.
Â
European Summary of Product Characteristics (SmPC) has been updated to reflect these two new contraindications. This change is limited to the European label only. The United States Package Insert is not affected and does not contain a contraindication for acute infiltrative lung disease or pericardial disease. The only contraindication in the U.S. label is for those patients with hypersensitivity to bortezomib, boron or mannitol.
Expressive Writing May Aid Cancer Patients
Researchers have found that a single, 20-minute writing session helped change the way some cancer patients thought or felt about their disease. That, in turn, seemed to improve how they rated their quality of life.
(from Reuters by way of Medline)
Mayo Clinic cancer model to speed up drug research
After a six-year effort, Mayo researchers in Scottsdale proved that a gene called MYC is instrumental in converting a benign tumor called MGUS into one that eventually becomes myeloma. (from the Arizona Republic)
New Biological Agents Added to Treatment Algorithm for Multiple Myeloma
Novel therapy using several targeted agents has been incorporated into new guidelines from the National Comprehensive Cancer Network (NCCN) for treatment of multiple myeloma (from Doctor's Guide)
Caring for Your Bones When You Have Multiple Myeloma
New from CancerCare's free Telephone Education Workshops
April 2, 2008 from 1:30 p.m. - 2:30 p.m. ET
Orphan drug designation granted for monoclonal antibody, BT-062
While chemotherapy attacks healthy tissue as well, BT-062 attaches itself selectively to a protein found in high densities in malignant cells. (from Ad-Hoc-News.de)
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
The company has initiated Phase I/II studies to evaluate the therapeutic potential of milatuzumab in patients with multiple myeloma (from PrimeNewswire)
Array BioPharma Advances p38 / Tie2 Inhibitor, ARRY-614, into Phase 1 Clinical Trial
Researchers believe the dual inhibition of p38 and Tie2 may produce additive and/or synergistic effects with other therapies in treating multiple myeloma. (from TradingMarkets.com)
Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
"Targeting Multiple Myeloma with Oncolytic Viral Therapy" covers preclinical work using reovirus as a purging agent during autologous stem cell transplants for multiple myeloma. (from CNW Telbac)
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Trial results of combination therapy VELCADE, melphalan and prednisone (VcMP) reported a 32 percent complete remission rate with 85 percent of patients alive at three years.(from PR News)
SpringAH, SPRING! Time to start planning your FUNdraisers!
From a day of beauty to a walk in the clouds, from yard sales to concerts, IMFers are creating fun days to raise money to help support the important work that the IMF is doing in both research and education. Here are some suggestions for your next event!
WHAT'S NEW IN RESEARCH
ARTICLES
(IMF Scientific Advisors are marked with an *)

    * Myeloma in patients under age 50 presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group
      Heinz Ludwig*, Brian G.M. Durie*, Vanessa Bolejack, Ingemar Turesson, Robert A. Kyle*, Joan Blade*, Rafael Fonseca*, Meletios Dimopoulos*, Kazuyuki Shimizu*, Jesus San Miguel*, Jan Westin*, Jean-Luc Harousseau*, Meral Beksac*, Mario Boccadoro*, Antonio Palumbo*, Bart Barlogie*, Chaim Shustik*, Michele Cavo, Douglas Joshua*, Michel Attal*, Pieter Sonneveld*, and John Crowley*
      Blood published 11 February 2008, 10.1182/blood-2007-03-081018

    * Appraisal of immunoglobulin free light chain as a marker of response
      Angela Dispenzieri, Lijun Zhang, Jerry A. Katzmann, Melissa Snyder, Emily Blood, Roberta DeGoey, Kim Henderson, Robert A. Kyle*, Martin M. Oken*, Arthur R. Bradwell, and Philip R. Greipp
      Blood published 25 March 2008, 10.1182/blood-2008-02-138602

    * Is tandem autotransplantation necessary in myeloma?
      Sundar Jagannath*
      Blood 2008;111 1751-1752

    * Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
      Abderrahman Abdelkefi, Saloua Ladeb, Lamia Torjman, Tarek Ben Othman, Amel Lakhal, Neila Ben Romdhane, Halima El Omri, Moez Elloumi, Hatem Belaaj, Ramzi Jeddi, Lamia Aissaoui, Habib Ksouri, Assia Ben Hassen, Fahmi Msadek, Ali Saad, Mohamed Hsairi, Kamel Boukef, Ahlem Amouri, Hechmi Louzir, Koussay Dellagi, and Abdeladhim Ben Abdeladhim, Â on behalf of the Tunisian Multiple Myeloma Study Group
      Blood 2008;111 1805-1810

    * The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells
      David J. J. de Gorter, Rogier M. Reijmers, Esther A. Beuling, Hildegonda P. H. Naber, Annemieke Kuil, Marie Jose Kersten, Steven T.
      Pals, and Marcel Spaargaren
      Blood 2008;111 3364-3372

    * Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders
      Linda Morris Brown, Gloria Gridley, David Check, and Ola Landgren
      Blood 2008;111 3388-3394

    * CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy
      Ping Zhou, Raymond L. Comenzo, Adam B. Olshen, Ezio Bonvini, Scott Koenig, Peter G. Maslak, Martin Fleisher, James Hoffman, Suresh
      Jhanwar, James W. Young, Stephen D. Nimer, and Adam M. Boruchov
      Blood 2008;111 3403-3406

    * The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma
      Manik Chatterjee, Christoph Rancso, Thorsten Stuhmer, Niels Eckstein, Mindaugas Andrulis, Christian Gerecke, Heike Lorentz, Hans-Dieter Royer, and Ralf C. Bargou
      Blood 2008;111 3714-3722

    * Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
      Ya-Wei Qiang, John D. Shaughnessy, Jr, and Shmuel Yaccoby
      Blood published 14 March 2008, 10.1182/blood-2007-10-120253

    * An analysis of the clinical and biological significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
      Wei Xiong, Xiaosong Wu, Sarah Starnes, Sarah K Johnson, Jeff Haessler, Siqing Wang, Lijuan Chen, Bart Barlogie*, John D Shaughnessy, Jr, and Fenghuang Zhan
      Blood published 13 March 2008, 10.1182/blood-2007-10-119123

    * Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
      Ya-Wei Qiang, Yu Chen, Owen Stephens, Nathan Brown, Bangzheng Chen, Joshua Epstein, Bart Barlogie*, and John D. Shaughnessy, Jr
      Blood published 27 February 2008, 10.1182/blood-2008-01-132134

    * Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared to monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability
      Tilmann Bochtler, Ute Hegenbart, Friedrich W Cremer, Christiane Heiss, Axel Benner, Dirk Hose, Marion Moos, Jelena Bila, Claus R Bartram, Anthony D Ho, Hartmut Goldschmidt*, Anna Jauch, and Stefan O Schonland
      Blood published 27 February 2008, 10.1182/blood-2007-11-122101

    * Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy
      Yulia Nefedova, Daniel M. Sullivan, Sophia C. Bolick, William S. Dalton, and Dmitry I. Gabrilovich
      Blood 2008;111 2220-2229

    * B cells: B cell back catalogue (remastered)
      Matthew C. Cook
      Immunology and Cell Biology (2008) 86, 109–110; published online 22 January 2008"

Fin de la cita.
Para más tener más informacion sobre cada uno de estos temas, hay que buscar en Google ,en "myeloma minute".
(Asi, cada uno soló lee lo que le interesa.)
Un saludo.

Gracias Victor y Annie.

Un saludo.

De nada!  
fuiste alli?
http://myeloma.org/main.jsp?tab_id=1&type=article&id=560
Un abrazo.